Bharat Biotech's Covaxin found 100% effective against 'severe Covid disease' in Phase-3 interim analysis
- In the trial results, Bharat Biotech and the ICMR said that Covaxin demonstrates an overall interim clinical efficacy of 78%
- The efficacy against severe Covid-19 disease was 100%, the company said
Hyderabad-based vaccine manufacturing firm Bharat Biotech on Wednesday announced the interim efficacy data for the phase 3 trials of Covaxin, the first made-in-India coronavirus vaccine.
Select your Category
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more